Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir plus ribavirin before liver transplant to prevent post-transplant HCV recurrence in HIV-HCV coinfected adults
2014-001739-35Phase 2Completed
- Sponsor
- University of Modena and Reggio Emilia
- Start
- Jul 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sofosbuvir and ribavirin in hepatitis C virus infection and human immunodeficiency virus infection (HIV), sponsored by University of Modena and Reggio Emilia. Primary endpoint: Sustained post-transplant virological response at 12 weeks post-transplant. Started Jul 2014; status: completed.
02
Drugs
sofosbuvirribavirin
03
Conditions
hepatitis C virus infectionhuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2014-001739-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001739-35.